Projet EDUC8 (Horizon 2020, appel à projets 2019)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

The development of anti-drug antibodies is the major complication of treatment with biotherapeutics. This is particularly true of patients with haemophilia A (HA) who develop neutralizing antibodies to therapeutic factor VIII (FVIII) following replacement therapy with exogenous pro-coagulant FVIII. The onset of neutralizing antibodies to FVIII, referred to as FVIII inhibitors, represents a major societal concern owing to the enormous cost associated to the clinical management of inhibitor-positive patients, that exceeds 200,000€/patient/year. The EDUC8 program is a multidisciplinary training program with exposure of the enrolled ESRs to a core common educational package and development of individual PhD research projects dedicated to decreasing the societal burden associated with the development of anti-FVIII antibodies in Europe. The core educational program includes exposure to basic science in the fields of immunology and hemostasis, to the most advanced “omic” technologies in order to anticipate tomorrow’s scientific discoveries, and to the importance of ethical considerations and public awareness in today’s research. A key component of the training program is provided by immersion of the ESRs in a clinical center for HA, which will provide them with a unique experience and foster the conception of novel and realistic therapeutic approaches. The ESRs will exploit the accumulated theoretic and practical experience in an entrepreneurship training on key strategic, technical, financial and human resource issues required for the creation of startups. In a tribute to the concept of the fully developed mind coined by the French philosopher Michel de Montaigne on education, our ambition is to form a novel generation of scientists with deep scientific knowledge, multicultural exposure, imagination, pragmatism and understanding of both the academic and private sectors. This will foster translational research in European on the immunogenicity of therapeutic proteins.

Mots clés : haemophilia a, factor viii, protein therapeutic, immunogenicity, anti drug antibodies, immuno intervention

Participants :
- University of Milan (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 261499.68 €
- Institut national de la santé et de la recherche médicale (France) — Coordinator, beneficiary, Recherche, subvention : 274802.04 €
- Goethe University Frankfurt (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 252788.4 €
- Dc4u (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 0.0 €
- Topas therapeutics gmbh (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 0.0 €
- University Hospital Bonn (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 252788.4 €
- Commissariat à l’énergie atomique et aux énergies alternatives (France) — Partner, beneficiary, Recherche, subvention : 274802.04 €
- Sanquin (Pays-Bas) — Partner, beneficiary, Recherche, subvention : 518401.47 €
- Amsterdam University Medical Centers (Pays-Bas) — Partner, beneficiary, Recherche, subvention : 265619.88 €